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Rationale: In November 2005, the American Thoracic and European Respiratory Societies
jointly published a statement proposing a new interpretation scheme for pulmonary
function tests. The practical effect of adoption of these new guidelines has not yet been
studied. The purpose of the current study was to address the effects of the new
interpretation strategy on the relative distribution of obstructive and restrictive diagnoses
in patients evaluated at a single academic medical center laboratory.
Patients/Methods: Pulmonary functions tests from 319 patients were analyzed according
to four different interpretation schemes. The number of patients classified according to
each as obstructed, restricted, neither, or both were compared, and factors associated
with a change in classification using the different approaches were examined.
Results: Although similar proportions of patients were identified as restricted using either
the ‘‘GOLD’’ scheme (23%) or new approaches (22%), significantly more (Po0.005) were
defined as obstructed using the newly proposed scheme (44% versus 33%). Additionally, 36%
of subjects defined as obstructed using either the traditional or new schemes were
classified differently (i.e., either ‘‘gained’’ or ‘‘lost’’ the diagnosis of obstruction) using
the new approach. Women were significantly more likely than men to have a change in
classification.
Conclusions: The new interpretation scheme leads to a diagnosis of obstruction in a
greater proportion of patients undergoing pulmonary function testing. The clinical
significance of this finding has not yet been validated, and its economic impact remains to
be assessed.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Table 1 Indications for pulmonary function testing.
Number of
patients
% (95% CI)
Symptom
Dyspnea 28 8.8 (6–12)
Abnormal chest X-ray 18 5.6 (3–9)
Cough 6 1.9 (1–4)
Hypoxemia 4 1.2 (0–3)
Others 8 2.5 (1–5)
Known or suspected
disease
Interstitial lung
disease
67 21.0 (17–26)
Sarcoidosis 59 18.5 (14–23)
Chronic obstructive
pulmonary disease
35 11.0 (8–15)
Asthma 25 7.8 (5–11)
Beryllium
exposure/disease
10 3.1 (2–6)
Lung cancer 9 2.8 (1–5)
Bronchiectasis 8 2.5 (1–5)
Congestive heart
failure/atrial
fibrillation
8 2.5 (1–5)
Collagen vascular
disease
6 1.9 (1–4)
Post-lung transplant 5 1.6 (1–4)
Neurologic disease 3 0.9 (0–3)
Cystic fibrosis 2 0.6 (0–2)
Pneumonia 2 0.6 (0–2)
Tracheal disease 2 0.6 (0–2)
Pleural disease 2 0.6 (0–2)
Preoperative evaluation 10 3.1 (2–6)
Indication not specified 2 0.6 (0–2)
Total 319
One case each of pulmonary alveolar proteinosis, pul-
monary hypertension, gastroesophageal reflux, wheezing,
Wegener’s granulomatosis, Crohn’s disease, chest pain, and
sleep apnea syndrome.
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In November 2005, the American Thoracic Society (ATS) and
European Respiratory Society (ERS) jointly published a
statement proposing a new interpretation scheme for
pulmonary function tests.1 The guidelines include several
substantive changes for many pulmonary function labora-
tories, including utilization of normal cutoff values based on
lower limits of normal (LLN). Although use of LLN was
recommended as far back as 1991,2 the standard has been
slowly adopted by many pulmonary function test (PFT)
laboratories. LLN are set at the 5th percentile of the
frequency distribution of values measured in the reference
population. When values are normally distributed, the 5th
percentile is equivalent to the 95th percentile confidence
interval. The guidelines suggest that LLN be used not only to
determine flow and volume abnormalities, but also to
evaluate ratios, such as FEV1/VC, in determining the
presence of obstruction. LLN are thought to be better than
a fixed cutoff of 80% predicted or FEV1/FVC less than 0.70,
since LLN better incorporate the expected changes in flow
that occur with normal aging in healthy individuals.3
In addition, the new guidelines advocate use of the ratio
of forced expiratory volume in 1 s (FEV1) to vital capacity
(VC), rather than to forced vital capacity (FVC), to
determine the presence of obstruction, where VC represents
the largest of the following three values: FVC, ‘‘slow’’ VC
(SVC), or forced inspiratory VC (FIVC). Furthermore, the
guidelines indicate that obstruction is diagnosed with a
normal FEV1/VC and TLC and a reduced VC—a criterion that
conceptually reflects obstruction which is severe enough to
prevent subjects from effectively exhaling to true residual
volume, thereby resulting in an underestimation of VC and a
falsely normal ratio of FEV1 to VC.
The newly proposed guidelines are likely to have an effect
on the proportion of individuals defined as abnormal. In
particular, since the LLN-based method better accounts for
reductions in flow associated with aging, use of this scheme
would be expected to result in a decreased frequency of
obstruction in the elderly. Conversely, use of FEV1/VC as the
basis for diagnosing obstruction may be expected to lead to an
increase in the frequency of those diagnosed as obstructed.
Finally, classification of patients with a normal FEV1/VC (and
TLC) and reduced VC would be anticipated to increase the
number of patients diagnosed with airway obstruction. The
magnitude of each of these effects is, however, unknown. This
study addresses the impact of the new interpretation strategy
on the relative distribution of obstructive and restrictive
diagnoses in patients evaluated at a single academic medical
center laboratory utilizing different interpretation schemes.
Methods
Patients
Three hundred and nineteen consecutive patients who
underwent full pulmonary function testing, including spiro-
metry and lung volumes, were included. The primary
indications for testing are listed in Table 1. Studies were
performed in the Pulmonary Diagnostics Laboratory of the
Hospital of the University of Pennsylvania over a 7-weekperiod. Prior to study initiation, permission was obtained
from the Institutional Review Board of the University of
Pennsylvania.Measurements
Studies were conducted according to new ATS/ERS standar-
dization guidelines for performance of spirometry4 and lung
volumes using body plethysmography.5 All studies met
criteria for acceptability and repeatability as defined in
the guidelines. Typical practice in our laboratory incorpo-
rates quality control measures, including daily instrument
calibration and review of study quality by a supervising
technician and physician prior to interpretation. All studies
were performed with patients in the seated position using a
Medical Graphics Elite DL (model number 830002-008).
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predicted normals for spirometry6 and European Community
for Coal and Steel (ECCS)-predicted normals for lung
volumes7 were utilized. For African-Americans, a 12%
correction for predicted TLC was applied; for Asians, a 6%
correction was applied for predicted FEV1, FVC, and TLC.
Four interpretation strategies were applied: (1) the
Global Initiative for Chronic Obstructive Lung Disease
(‘‘GOLD’’) approach,8 using an FEV1/FVC cutoff of 0.70 to
define obstruction and TLCo80% predicted to define
restriction (Method 1); (2) an approach based on the 1991
ATS guidelines,2 defining obstruction as FEV1/FVCoLLN and
restriction as TLCoLLN (Method 2); (3) an approach based
on FEV1/VC, defining obstruction as FEV1/VCoLLN and
restriction as TLCoLLN (Method 3); and (4) the newest
ATS/ERS method, defining obstruction as FEV1/VCoLLN or
VCoLLN if FEV1/VCXLLN and TLCXLLN; restriction was
defined as TLCoLLN (Method 4). In Methods 3 and 4, VC was
the greatest of FVC, slow vital capacity (SVC), and forced
inspiratory vital capacity (FIVC).
Patients were classified as normal, obstructed, restricted,
or obstructed and restricted. Anticipating that proposed
changes would have their greatest impact on the
diagnosis of obstruction, an additional category of ‘‘any
obstruction,’’ which includes patients with pure obstruction
or a combined defect, was created. Data on height, weight,
body mass index (BMI), age, and race were also collected.
Each patient had only one set of tests performed during the
study period.Statistical methods
To determine if proportions of subjects falling within
diagnostic categories were different for each classification
scheme, we first performed an overall test of homogeneity
of proportions using chi-square analysis of an RC table. If
a difference was found, pair-wise chi-square statistics were
used to compare proportions between two interpretations to
determine which proportions were different.
In addition to overall interpretation method-based
differences in proportions of patients within each diagnostic
category, we evaluated whether individual patients were
categorized differently based on the algorithm used.
Specifically, a discordance proportion, which defines those
subjects whose diagnostic category changed from one
strategy to the next, was determined. Appropriate 95%
confidence intervals were calculated for the proportions.
For patients with obstruction (pure obstruction or mixed
obstruction–restriction), we examined effects of race,
gender, age, and BMI on results using Methods 1 and 4. An
analogous approach using RC tables was constructed for
categorical variables, allowing comparison of proportions
among those for whom the two approaches agreed and those
who ‘‘gained’’ or ‘‘lost’’ the diagnosis of obstruction using
each interpretation method.
Our study was powered at 80% to detect an increase or
decrease of 12% in the proportion of subjects defined as
obstructed or restricted, assuming a baseline prevalence of
abnormality of 30% and an alpha level of 0.05.
Analyses were performed using STATA version 7.0 (STATA
Data Corp., College Station, TX).Results
Patient population
Pulmonary function test results from 319 consecutive
patients were analyzed (Table 2). The average age of
study participants was 57 years (range 18–84). Fifty-
seven percent were female; 71% were Caucasian, and 27%
African-American. The mean BMI was 30 (range
13–68). Mean percent predicted values for pulmonary
function tests were as follows: FEV1, 72724; FVC, 77722;
SVC, 80721; FIVC, 73721, FEV1/FVC, 94719; and TLC,
92723.Proportions of subjects within each diagnostic
category based on interpretation strategy
Table 3 shows the absolute numbers and proportions
of patients defined as having pure obstruction, pure
restriction, neither obstruction nor restriction, com-
bined obstruction–restriction, or any obstruction based
upon application of each of the four interpretation
methods.
Application of each method resulted in the same propor-
tion of patients diagnosed with restriction (22–24%).
However, use of Method 2 (based on use of LLN cutoff for
FEV1/FVC as recommended in the 1991 ATS guidelines)
resulted in a smaller proportion of patients catego-
rized as obstructed alone (21% versus 30%, 29%, and 39%
for Methods 1, 3, and 4, respectively; P ¼ 0.003) or as
having obstruction with or without restriction—i.e., any
obstruction (23% versus 33%, 33%, and 43% for Methods
1, 3, and 4, respectively; P ¼ 0.002) compared with any of
the other three methods. In addition, a greater prop-
ortion of patients were categorized as having neither
obstruction nor restriction using Method 2 compared
with Methods 1, 3, or 4 (54% versus 45%, 46%, and 35%,
respectively; P ¼ 0.001). Methods 1 and 3 resulted in
similar proportions of patients categorized as obstr-
ucted (30% versus 29%, respectively; P ¼ 0.36). However,
application of Method 4, which incorporates all of the
changes recommended in the newest ATS/ERS guidelines,
resulted in significantly more patients categorized as
obstructed than did any of the other methods (43% versus
33%, 23%, and 33% for Methods 1, 2, and 3, respectively;
P ¼ 0.005).Discordance within obstructive category
When using either Method 1 (the GOLD method) or Method 4
(the newest ATS/ERS method), a total of 147 subjects
were defined as obstructed in one scheme or the other.
For 94 patients (64%; 95% CI: 56–72), the two schemes
agreed. However, for the other 53 patients (36%; 95%
CI: 28–44), the methods were discordant. Compared
with Method 1, application of Method 4 resulted in 43%
or 29% (95% CI: 22–37) of patients newly categorized
as obstructed and 10 or 7% (95% CI: 3–12) no longer
categorized as obstructed.
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Table 3 Proportions of subjects with each diagnosis according to interpretation method.
Method 1 Method 2 Method 3 Method 4
N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI)
Restricted 72 23 (18–28) 75 24 (19–29) 69 22 (17–27) 69 22 (17–27)
Obstructed 95 30 (25–35) 66 21 (16–26)* 92 29 (24–34) 125 39 (34–45)%
Neither 143 45 (39–50) 172 54 (48–59)! 146 46 (40–51) 113 36 (30–41)$
Both 9 3 (1–5) 6 2 (1–4) 12 4 (2–6) 12 4 (2–6)
Any obstruction 104 33 (27–38) 72 23 (18–28)] 104 33 (27–38) 137 44 (37–49)@
Method 1: ‘‘GOLD’’ approach; Method 2: based on LLN; Method 3: based on FEV1/VCoLLN; Method 4: new ATS/ERS approach, including
diagnosis of obstruction based on FEV1/VCoLLN or VCoLLN if FEV1/VCXLLN and TLCXLLN.
*Po0.003 versus Methods 1, 3, or 4.
%Po0.01 versus Methods 1 or 3.
!Po0.001 versus Methods 3 or 4.
]Po0.002 versus Methods 1, 3 or 4.
$Po0.04 versus Methods 1, 2, or 3.
@Po0.004 versus Methods 1 or 3.
Table 2 Characteristics of the study population.
N % 95% confidence interval
Race
Black 86 27 22–32
Caucasian 228 71 66–76
Other 5 2 0.5–4
Gender
Male 137 43 37–49
Female 182 57 51–63
Mean Range 5th Percentile 95th Percentile
Age (years) 56.5 18–84 33 78
Weight (lbs) 183 83–375 115 267
BMI 30 13–68 19.7 44.4
FEV1 (L) 2.05 0.47–5.22 1 4
FEV1% predicted 72 15–152 31 107
FVC (L) 2.84 0.75–5.9 1.3 4.9
FVC% predicted 77 25–150 40 110
FEV1/FVC 73 25–100 41 90
FEV1/FVC% predicted 94 22–127 51 118
TLC (L) 5.1 2.42–10.18 3 8
TLC% predicted 92 34–154 51 127
SVC 2.95 0.76–5.85 1.4 5.1
SVC% predicted 80 26–156 43 111
FIVC 2.71 0.36–5.89 1.2 4.8
FIVC% predicted 73 10–141 37 106
Significantly different from FVC and SVC; Po0.001 for each.
Impact of new PFT guidelines 2339Effect of inhaled bronchodilators on disease
classification
Technically, for the diagnosis of obstruction the ‘‘GOLD’’
criteria require use of post-inhaled bronchodilator spirome-
try for determination of FEV1/FVC. Only 113 patients in our
study population had inhaled bronchodilators ordered aspart of their evaluation. We examined the effect of using
pre- and post-bronchodilator FEV1/FVC on the proportion
of patients diagnosed as obstructed, compared with use of
pre-bronchodilator spirometry analyzed according to the
new ATS/ERS guidelines (Method 4, above). The results are
seen in Table 4. The proportions of subjects diagnosed as
obstructed are similar using pre- and post-bronchodilator
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Table 4 Comparison of application of pre- and post-bronchodilator spirometry using ‘‘GOLD’’ criteria and new ATS/ERS
standards on disease classification.
Pre-bronchodilator FEV1/FVC%o70;
N (%, 95% CI)
Post-bronchodilator FEV1/FVC%o70;
N (%, 95% CI)
New ATS/ERS standards;
N (%, 95% CI)
Restriction 16 (14.2, 8.3–22.0) 18 (15.9, 9.7–24.0) 15 (13.3, 7.6–20.9)
Obstruction 61 (54.0, 44.3–63.1) 60 (53.1, 43.5–62.5) 73 (64.6, 55.0–73.4)
Neither 31 (27.4, 19.5–36.6) 32 (28.3, 20.2–37.6) 19 (16.8, 10.4–25.0)
Both 5 (4.4, 1.5–10.0) 3 (2.7, 0.6–7.6) 6 (5.3, 2.0–11.2)
Any obstruction 66 (58.4, 48.8–67.6)@ 63 (55.8, 46.1–65.1) 79 (69.9, 60.6, 78.2)*,]
Total 113.
@P ¼ 0.34 compared with post-bronchodilator FEV1/FVC%.
*Po0.04 compared with pre-bronchodilator FEV1/FVC%.
]Po0.01 compared with post-bronchodilator FEV1/FVC%.
M.E. Kreider, M.A. Grippi2340measurements according to the ‘‘GOLD’’ methodology (58%
and 55%, respectively; P ¼ 0.34) and significantly less than
the proportion diagnosed using the new ATS/ERS standards
(Po0.04 for each).
Effects of race, gender, age, and BMI on distribution
of obstructive category
The effects of race, gender, age, and BMI on the distribution
of patients diagnosed with obstruction using Methods 1 and 4
were examined (Table 5). Significant overall differences in
diagnostic categorization emerged based on gender only
(P ¼ 0.01). Using Method 4, women were significantly more
likely than men to ‘‘gain’’ a diagnosis of obstruction
(P ¼ 0.007), and men were significantly more likely than
women to ‘‘lose’’ the diagnosis (P ¼ 0.03).
Discussion
This study demonstrates that, compared with the ‘‘GOLD’’
criteria, application of the newly proposed pulmonary
function test interpretation guidelines of the American
Thoracic and European Respiratory Societies results in an
increase of approximately 10% in the number of patients
categorized as obstructed. In addition, application of the
newly proposed scheme results in a 36% discordance rate for
patients categorized as obstructed using either the ‘‘GOLD’’
or newly proposed schemes.
Inspection of the findings from application of each of the
four methods described elucidates the criterion that
accounts for the increase in proportion of patients classified
as obstructed. Use of the lower limit of normal to define
abnormality (Method 2) and incorporation of a more
inclusively defined vital capacity into the FEV1/VC criterion
(Method 3) appear to have equal and opposite effects in
defining the presence of obstruction. In particular, use of
Method 2 resulted in 23% of patients diagnosed as having any
obstruction, compared with 33% using Method 1. Since
Method 3 demonstrated no difference from Method 1 in the
proportion of patients diagnosed as having any obstruction
(33% versus 33%), the effect of using the LLN-based
methodology is likely offset by application of the FEV1/VC
standard. Hence, the principal basis for the observed 10%increment in obstruction appears to be application of the
criterion of a reduced VC in the setting of a normal FEV1/VC
and normal TLC. Furthermore, the increase in proportion of
patients classified as obstructed is accounted for largely
by women.
Importantly, not only was a higher proportion of patients
diagnosed as obstructed under the new scheme, 36% of
patients were categorized differently. In effect, patients
who previously were told, or would have been told,
that they were normal would now be told that they
have abnormal lung function. Conversely, patients who
were told, or would have been told, that they had abnormal
lung function would now be told their lung function is
normal.
Based upon a variety of studies conducted in the United
States and Europe, we know that clinical practice guidelines
are not regularly adopted into clinical practice. In fact, only
30–40% of patients receive care according to established
guidelines.9 Reasons for the slow adoption of practice
guidelines have been examined in a variety of conditions
and include financial disincentives for practitioners; organi-
zational constraints in guideline implementation, including
lack of time; patient expectations regarding clinicians’
skills; longstanding tradition in clinical practice and train-
ing; clinician self-confidence in skills; concerns about
‘‘information overload;’’ and uncertainty over the true
benefit of implementing guidelines.9 The application of
diagnostic algorithms may face many of the same barriers.
In practical terms, financial disincentives and organiza-
tional constraints may include the need to create or
purchase new software or to adapt existing software as a
means of incorporating the proposed interpretation
changes, thereby affecting the training of technicians and
interpreting physicians. Additionally, the new guidelines
may be viewed as burdensome with regard to effort and
time required for implementation. Indeed, the new pul-
monary function test interpretation guidelines are more
reliant upon measurement of lung volumes to confirm a
diagnosis of restriction or obstruction. Since measurements
of lung volume take longer than does spirometry alone,
assessment of lung volumes may be quite problematic for
many laboratories. Finally, even the experts who collabo-
rated in developing these guidelines are not in complete
agreement about the value of all of the proposed changes.10
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Table 5 Effects of race, gender, age, and BMI on distribution of obstructive category.
Number of patients demonstrating
concordance between Methods 1
and 4 (%, 95% CI)
Number of patients who ‘‘gained’’
diagnosis of obstruction using
Method 4 (%, 95% CI)
Number of patients who ‘‘lost’’
diagnosis of obstruction using
Method 4 (%, 95% CI)
Total
Total 94 (64, 56–72) 43 (29, 22–37) 10 (7, 3–12) 147
Race
African-
American
27 (51, 37–65) 15 (35, 21–51) 1 (2, 0.004–10) 43
Caucasian 66 (64, 54–73) 28 (27, 19–37) 9 (9, 4–16) 103
Other 1 0 0 1
Gender
Female] 52 (60, 49–70) 32 (37, 27–48)* 3 (3, 0.7–10)^ 87
Male 42 (70, 57–81) 11 (18, 10–30) 7 (12, 5–23) 60
Age (years,
mean7SD)
58714 57713 61712
BMI 2878 32710 2774
]P ¼ 0.01 for overall comparison of men versus women.
*P ¼ 0.007 versus men who ‘‘gained’’ diagnosis of obstruction.
^P ¼ 0.03 versus men who ‘‘lost’’ diagnosis of obstruction.
Impact of new PFT guidelines 2341The new guidelines require that physicians use an
unfamiliar and somewhat less intuitive, although statisti-
cally more robust, approach. Decline in ‘‘normal’’ FEV1/FVC
with increasing age has been well documented,6 and the
value of using a more statistically meaningful value of LLN
that incorporates these changes is not a new concept.2 In
fact, this recommendation has been in place since 1991,
although many pulmonary function laboratories have not
adopted the approach. Additionally, other aspects of the
new guidelines have not yet been prospectively validated
with respect to disease outcome. For instance, a new
group of patients with a normal FEV1/VC are now diagnosed
as having obstructive lung disease. These patients are
not represented in previous studies of morbidity, mortality,
or drug effectiveness. Studies of subjects with asthma11,12
and chronic airways disease13 demonstrate that this pattern
can be seen with those diseases. Does this mean that all
subjects with that are pattern diseased? Do they behave
over time in a way similar to traditional asthmatics? Can
conclusions from previous studies based on inclusion criteria
of a reduced FEV1/FVC be safely generalized to this new
population, or does this group represent a unique form of
obstructive lung disease? Additionally, how do we reconcile
observations in these subjects with findings on, and
recommendations for, the diagnosis and therapy of obstruc-
tive airway disease, such as the Global Initiative for Chronic
Obstructive Lung Disease?8,14 Finally, what are the clinical
and cost implications of evaluating more women for
obstruction than would have been identified under the old
scheme?
The current study was limited to a single academic
center. Since our tertiary center includes several subspeci-
alty programs, e.g., lung transplantation and specialized
programs in interstitial lung disease and emphysema, we
may be expected to see a skewed distribution of patients
with more advanced disease than do community-based
clinicians. However, examination of the basis for pulmonaryfunction testing (Table 1) reveals a broad spectrum of
indications for testing, making this limitation less relevant.
Of additional note, we have a large percentage of subjects
undergoing evaluation for sarcoidosis and a variety of
interstitial lung diseases which demonstrate restriction on
pulmonary function testing. Despite this relatively large
proportion of restrictive disorders, our finding of a sub-
stantial increase in the number of obstructive diagnoses
suggests that in many practices, even more airway obstruc-
tion will be diagnosed using the new criteria. Our medical
center’s patient population does include a relatively
small number of Hispanics, Asians, and other minorities.
Therefore, the impact of the new guidelines on these
subgroups cannot be readily determined on the basis of our
findings.
The current study demonstrates that the recently proposed
guidelines for pulmonary function test interpretation identify
a new subset of patients as obstructed. These subjects, who
have proportionate reductions in FEV1 and VC, preserved
FEV1/VC, and normal lung volumes may, indeed, have airway
obstruction that has been noted in studies of patients with
known airways disease. Alternatively, they may be individuals
who are limited in their ability to exhale completely, thereby
generating falsely low spirometry values. While all of the tests
included in our study met ATS criteria for acceptability and
repeatability, conceivably, other technical issues may affect
test performance. Therefore, future studies should examine
end-of-test criteria and address acquisition of corroborating
evidence to support a diagnosis of obstruction (e.g.,
measurements of airway resistance).
In summary, the new ATS/ERS guidelines for interpreta-
tion for pulmonary function testing incorporate changes that
may have a significant impact on the diagnosis of obstructive
lung disease. Potential implications of these findings include
the recognition of a new subset of patients with obstruction,
the clinical significance of which is unknown, and identifica-
tion of a number of patients newly defined as having lung
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therapy.
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